OR WAIT null SECS
January 28, 2022
PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.
BenchSci, a specialist in machine learning applications for novel medicine development, has completed a Series C financing round.
Scottish biotech engineering company, uFraction8, has successfully secured more than £2.5 million ($3.3 million) in new investment.
NICE has updated its Technology Appraisal Guidance TA599 for AstraZeneca’s Lokelma.
Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.
January 27, 2022
Merger with Phlexglobal expands provider’s technological capabilities.
A collaboration and licensing agreement has been entered into by the Queen’s University Belfast and Ipsen.
BIA and Clarivate have released new data that show there was a jump of 60% in investments into biotech and life sciences companies in the UK during 2021.
Stevanato Group has extended its licensing agreement with Haselmeier for its Axis-D pen injector technology.
January 26, 2022
Delays in sponsors providing postapproval evidence of effectiveness for therapies benefitting from streamlined FDA regulatory pathways are generating pressure for further review and reform of the agency’s accelerated approval process.
